Powered by HealthTechMovers.com
We added 5 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Seagen, SGEN
Summary: Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries. Seagen has an agreement with Takeda Pharmaceutical Company Ltd. for the further development and commercialization of Adcetris. Seagen retains all rights to sell Adcetris in the U.S. and Canada, while Takeda has commercial rights to the drug in the rest of the world. The FDA granted approvals to Seagen's several drugs named Padcev, for treating advanced/metastatic urothelial cancer; Tukysa and Tivdak for treating adult patients with locally advanced/metastatic HER2-positive breast cancer and for the treatment of recurrent/metastatic cervical cancer in adult patients respectively. The company also has license agreements with partners like Merck, Roche, GlaxoSmithKline, Astellas, AbbVie, Bristol-Myers and Genmab.
- Last Price: $200.3
- Price Change: -$0.18, -0.09%
- Yearly Gain: 40.38%
- Market Cap: $37.35B
- P/E Ratio: -60.674
Here are 3rd party ratings for SGEN:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 37% (92 out of 249)
What is the sentiment on the street regarding Seagen ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus: Bullish
- Media Buzz: Very High
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in SGEN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on SGEN before you decide to make any investment.
Click here for chart >>
Centene, CNC
Summary: Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Through a diversified product portfolio and expanding geographic reach, Centene continues to deliver results by growing premium and service revenues profitably. The company operates in two segments: Managed Care and Specialty Services. Managed Care - This segment provides health plan coverage to individuals through Government subsidized programs, including Medicaid. Specialty Services - This segment consists of its specialty companies offering diversified healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups and other commercial organizations.
- Last Price: $62.55
- Price Change: -$0.64, -1.01%
- Yearly Gain: -27.98%
- Market Cap: $35.03B
- P/E Ratio: 31.076
Here are 3rd party ratings for CNC:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 12% (219 out of 249)
What is the sentiment on the street regarding Centene ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Positive
If you are interested in CNC or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CNC before you decide to make any investment.
Click here for chart >>
Axsome Therapeutics, AXSM
Summary: Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.
- Last Price: $62.74
- Price Change: -$0.5, -0.79%
- Yearly Gain: 88.16%
- Market Cap: $2.69B
- P/E Ratio: -13.811
Here are 3rd party ratings for AXSM:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 37% (92 out of 249)
What is the sentiment on the street regarding Axsome Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Very Positive
If you are interested in AXSM or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on AXSM before you decide to make any investment.
Click here for chart >>
Compass Therapeutics, CMPX
Summary: Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based in Boston, MA.
- Last Price: $3.4
- Price Change: -$0.02, -0.58%
- Yearly Gain: 135.86%
- Market Cap: $449.24M
- P/E Ratio: -8.499
Here are 3rd party ratings for CMPX:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 37% (92 out of 249)
What is the sentiment on the street regarding Compass Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Very Positive
If you are interested in CMPX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CMPX before you decide to make any investment.
Click here for chart >>
MacroGenics, MGNX
Summary: MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland.
- Last Price: $6.65
- Price Change: -$0.34, -4.86%
- Yearly Gain: -21.72%
- Market Cap: $389.75M
- P/E Ratio: -3.579
Here are 3rd party ratings for MGNX:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 41% (147 out of 249)
What is the sentiment on the street regarding MacroGenics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Very High
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Positive
If you are interested in MGNX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on MGNX before you decide to make any investment.
Click here for chart >>
Thanks for reading!
